Q-omics provides the consensus-scored TTC19 profile across patient tissues and cancer cell-line models. TTC19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC19 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, TTC19 RNA expression shows 20,513 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where TTC19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC19 survival associations across molecular data types. TTC19 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC19 RNA expression–survival associations across cancer types. High TTC19 expression shows unfavorable associations in UVM, HNSC, KICH and LUAD, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC19 RNA expression.
This table summarizes TTC19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTC19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC19 shows lower tumor expression in KICH, KIRC, LUSC, THCA and LUAD and higher tumor expression in CHOL. The KICH box plot shows higher TTC19 RNA expression in normal versus tumor tissue (log2 FC = −1.494, t-test p < 0.001).
This table shows molecular features associated with TTC19 in patient tissues and cancer cell lines. In patient samples, TTC19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
